Get Permission Thakur and Kalsi: Onychomycosis due to Trichophyton violaceum in HIV/AIDS patients of sub-Saharan Africa


Introduction

Onychomycosis is due to chronic fungal infection of fingers and toenails. This infection is usually caused by dermatophytes, yeasts, and non-dermatophyte molds (NDM).1, 2, 3 In different regions of the world, different dermatophytes are responsible for various clinical types of onychomycosis. It also depends upon the predominant species prevalent in that particular geographical region. Infection of toenails is common in HIV-positive patients. In HIV-uninfected population the distal subungual pattern is the most common and occurs when fungus invades the nail bed in the distal hyponychial area.4 Proximal white subungual onychomycosis is the rarest form of onychomycosis in the general population, but this form has been associated with AIDS and is considered an early clinical marker of HIV infection.5

Earlier, the dermatophytes were divided into three genera: Trichophyton, Epidermophyton and Microsporum. But according to a recent study by Hoog et al., using multilocus sequencing, there are nine genera; Arthroderma, Ctenomyces, Epidermophyton, Lophophyton, Microsporum, Nannizzia, Trichophyton, Guarromyces, and Paraphyton.6 Onychomycosis is commonly due to Trichophyton species.

It has been estimated that 90% of toenails and 75% of fingernails onychomycosis are caused by dermatophytes especially Trichophyton interdigitale (T. interdigitale) and Trichophyton rubrum (T. rubrum).7, 8 Dermatophytes are usually associated with 90% cases of onychomycosis of the toenails and about 50% of fingernail infections. 9 The prevalence of onychomycosis has been found to be more in patients with HIV/AIDS and Onychomycosis usually appears with a CD4 cell count of <450 cells/mm3.10 Multiple or ten fingernails involvement due to T. violaceum is a typical sign of HIV/AIDS.1[Figure 1A]

The prevalence of onychomycosis in the Canadian and Brazilian samples from patients, who were HIV positive, was 24.0% (96 of 400) and 20.0% (20 of 100) respectively. 11 In an Indian study, the prevalence was found to be 24% (60 of 250).12

Different recognized forms of onychomycosis are: distal and lateral subungual, superficial, proximal subungual, mixed, endonyx, totally dystrophic, and secondary onychomycosis. 13

Laboratory Diagnosis

The fungal culture is considered to be the gold standard diagnostic technique. The subungual debris and nail clipping are collected after cleaning nails with soap and water and then scrubbing it with 70% alcohol. Sabouraud’s dextrose agar (SDA) is used with chloramphenicol and the second plate with Chloramphenicol and cycloheximide. The one with both chloramphenicol and cycloheximide will encourage growth of dermatophyte and the one without cycloheximide will allow NDMs to grow. Culture also confirms the viability of the fungus (white, purple and brown variants) [Figure 1E,F,G]. The culture plates are incubated at 250 C for 3 weeks and then morphology is studied by Lactophenol cotton blue mount (LPCB) [Figure 1B,C,D] and biochemical characteristics.

The other recent diagnostic techniques are dermoscopy, optical coherence tomography (OCT), confocal microscopy, Matrix-Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF), Polymerase chain reaction (PCR).

Figure 1

A: Onychomycosis due to T. violaceum in a 10-year-old HIV positive male child; B,C,D: LPCB mount showing rare macroconidia; D: Septate hyphae; E Colonies of white variant; F: Violet colonies; G: Brown colonies of T. violaceum.

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/f3fa87f4-55a2-4e42-8f00-342c6ce21d42image1.png
Table 1

Onychomycosis due to Trichophyton violaceum in patients of HIV/AIDS

S.No.

Author, Place and year

Immune status

Finger Nail

Toe nails

Type of involvement

1.

Thakur, Botswana, 2018 1

HIV+

Multiple & Ten

0

Endonyx, Total Dystrophic Onychomycosis

2.

Ravnborg, 1998 2

HIV+

Fingernails

0

Endonyx, Total Dystrophic Onychomycosis

Discussion

Prevalence of onychomycosis in the general population varies from 2-18%. 14 The prevalence onychomycosis in people with HIV/ AIDS is much higher and has a prevalence of 20– 44%. 15, 16

There are not many studies on onychomycosis in sub-Saharan Africa. So, it’s actual prevalence in HIV/AIDS patients is not known. But, in some of the countries of sub-Saharan Africa, T. rubrum is rare and the predominant species is T. violaceum, e.g. Botswana,1 tinea unguium was found to be the most frequent clinical type of dermatophytosis. In almost all cases of onychomycosis due to T. violaceum, fingernail (multiple or ten) involvement was found, and the clinical type was endonyx or total dystrophic onychomycosis.

The infection of nails are permanent source of infection and morbidity and can put the patient in embarrassing position, and low self-esteem, especially when fingernails are involved. The danger of deep infections in patients are more if onychomycosis is due to T. rubrum especially in immunosuppressed individuals. Deep infections due to T. violaceum is rare even in patients of HIV/AIDS.

Conclusion

There is a very high prevalence of T. violaceum in Africa and especially in sub-Saharan Africa. 17 Also, the prevalence of HIV/AIDS is very high in most of the countries. So, the patients with onychomycosis due to T. violaceum should be high. Onychomycosis should be investigated and patient’s HIV status should be tested and, the treatment should be given accordingly.

It has been found that the incidence of onychomycosis has decreased in HIV/AIDS patients due to introduction of combined Antiretroviral therapy (cART, because it has enabled HIV- infected individuals to have undetectable viral load and high CD4 cell counts, so their immunity become close to normal. 18

Additionally, it has been observed that the onychomycosis severity Index (OSI), 19 decrease after treatment with cART 20 and use of prophylactic fluconazole indicated for invasive opportunistic fungal infections also contributes towards the cure of onychomycosis. 21 Tinea capitis due to T. violaceum, or any other dermatophyte infection, if present, should be treated, because this can be a source of perpetual infection, especially due to frequent scratching with fingernails.

Source of Funding

None.

Conflict of Interest

None.

References

1 

R Thakur AS Kalsi Clinico-mycological study of onychomycosis in BotswanaJ Dermat Cosmetol2018269510010.15406/jdc.2018.02.00095

2 

L Ravnborg N Baastrup E Svejgaard Onychomycosis in HIV-infected patientsActa Derm Venereol1998782151210.1080/000155598433566

3 

A Husain N M Alam Y Joarder Correlation between clinical and mycological diagnosis of onychomycosisJ Pak Assoc Dermatol20172732205

4 

R Aly T Berger Common superficial fungal infections in patients with AIDSClin Infect Dis199622Suppl 2S12832

5 

K Weismann EA Knudsen C Pedersen White nails in AIDS/ARC due to Trichophyton rubrum infectionClin Exp Dermatol198813124510.1111/j.1365-2230.1988.tb00643.x

6 

GS De Hoog K Dukik M Monod A Packeu D Stubbe M Hendrickx Toward a Novel Multilocus Phylogenetic Taxonomy for the DermatophytesMycopathologia20171821-253110.1007/s11046-016-0073-9

7 

A K Gupta R G Sibbald A Andriessen R Belley A Boroditsky M Botros Toenail onychomycosis - A Canadian approach with a new transungual treatment: Development of a clinical path- wayJ Cutan Med Surg2015195440910.1177/1203475415581310

8 

A Joyce A K Gupta L Koenig R Wolcott J Carviel Fungal diver- sity and onychomycosis: An analysis of 8,816 toenail samples us- ing quantitative PCR and next-generation sequencingJ Am Podiatr Med Assoc201910915763

9 

MA Bodman K Krishnamurthy OnychomycosisStatPearls. Treasure Island (FL): StatPearls Publishing2022

10 

L Ravnborg N Baastrup E Svejgaard Onychomycosis in HIV-infected patientsActa Derm Venereol19987821512

11 

AK Gupta P Taborda V Taborda Epidemiology and prevalence of onychomycosis in HIV-positive individualsInt J Dermatol200039107465310.1046/j.1365-4362.2000.00012.x

12 

A Surjushe R Kamath C Oberai D Saple M Thakre S Dharmshale A clinical and mycological study of onychomycosis in HIV infectionIndian J Dermatol Venereol Leprol200773639740110.4103/0378-6323.37057

13 

RJ Hay R Baran Onychomycosis: A proposed revision of the clinical classificationJ Am Acad Dermatol201165612192710.1016/j.jaad.2010.09.730

14 

D Farhi J Savary S Pansart S Hesse Étude prospective des onychomycoses des pieds en France : prévalence, aspect clinique, impact et prise en charge en médecine généraleProspective study of feet onychomycosis in France: Prevalence, clinical aspect, impact and management in general practiceJ Mycol Med20112142667210.1016/j.mycmed.2011.10.005

15 

AK Gupta P Taborda V Taborda J Gilmour A Rachlis I Salit Epidemiology and prevalence of onychomycosis in HIV- positive individualsInt J Dermatol200039107465310.1046/j.1365-4362.2000.00012.x

16 

H Singh P Singh P Tiwari V Dey N Dulhani A Singh Dermatolog- ical manifestations in HIV-infected patients at a tertiary care hospital in a tribal (Bastar) region of Chhattisgarh, IndiaIndian J Dermatol20095443384110.4103/0019-5154.57609

17 

O Coulibaly C L'Ollivier R Piarroux S Ranque Epidemiology of human dermatophytoses in AfricaMed Mycol20185621456110.1093/mmy/myx048

18 

G Moreno-Coutiño Onychomycosis in Patients Living with HIV/AIDSCurr Fungal Infect Rep2019131697410.1007/s12281-019-00348-4

19 

C Carney A Tosti R Daniel A new classification system for grading the severity of onychomycosis: Onychomycosis Severity IndexArch Dermatol20111471112778210.1001/archdermatol.2011.267

20 

P Ruíz-López G Moreno-Coutiño R Fernández-Martínez J Espinoza-Hernández P Rodríguez-Zulueta G Reyes-Terán Evaluation of improvement of onychomycosis in HIV-infected patients after initiation of combined antiretroviral therapy without antifungal treatmentMycoses20155895162110.1111/myc.12350

21 

P Venkatesan J Perfect S Myers Evaluation and management of fungal infections in inmunocompromised patientsDermatol Ther2005181445710.1111/j.1529-8019.2005.05001.x



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 08-03-2023

Accepted : 15-03-2023


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijced.2023.002


Article Metrics






Article Access statistics

Viewed: 583

PDF Downloaded: 151



Medical Abbreviation List